Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, Al-Daghri NM, Herrero-Beaumont G, Martel-Pelletier J, Pelletier JP, Rannou F, Rizzoli R, Roth R, Uebelhart D, Cooper C, Reginster JY.

Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008. [Epub ahead of print] Review.

2.

Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Honvo G, Bannuru RR, Bruyère O, Rannou F, Herrero-Beaumont G, Uebelhart D, Cooper C, Arden N, Conaghan PG, Reginster JY, Thomas T, McAlindon T.

Drugs Aging. 2019 Apr;36(Suppl 1):145-159. doi: 10.1007/s40266-019-00667-8.

3.

Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?

Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, Rannou F, Roth R, Uebelhart D, Reginster JY.

Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1. Review.

4.

Chondrocyte enlargement is a marker of osteoarthritis severity.

Gratal P, Mediero A, Sánchez-Pernaute O, Prieto-Potin I, Lamuedra A, Herrero-Beaumont G, Largo R.

Osteoarthritis Cartilage. 2019 Aug;27(8):1229-1234. doi: 10.1016/j.joca.2019.04.013. Epub 2019 Apr 30.

PMID:
31051241
5.

Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression.

Herrero-Beaumont G, Pérez-Baos S, Sánchez-Pernaute O, Roman-Blas JA, Lamuedra A, Largo R.

Biochem Pharmacol. 2019 Jul;165:24-32. doi: 10.1016/j.bcp.2019.02.030. Epub 2019 Feb 27. Review.

PMID:
30825432
6.

Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy.

Estañ MC, Fernández-Núñez E, Zaki MS, Esteban MI, Donkervoort S, Hawkins C, Caparros-Martin JA, Saade D, Hu Y, Bolduc V, Chao KR, Nevado J, Lamuedra A, Largo R, Herrero-Beaumont G, Regadera J, Hernandez-Chico C, Tizzano EF, Martinez-Glez V, Carvajal JJ, Zong R, Nelson DL, Otaify GA, Temtamy S, Aglan M, Issa M, Bönnemann CG, Lapunzina P, Yoon G, Ruiz-Perez VL.

Nat Commun. 2019 Feb 15;10(1):797. doi: 10.1038/s41467-019-08548-9.

7.

A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A.

Pérez-Ferro M, Romero-Bueno FI, Serrano Del Castillo C, Mahillo I, Alvear A, Largo R, Herrero-Beaumont G, Sánchez-Pernaute O.

Clin Exp Immunol. 2019 Jun;196(3):336-344. doi: 10.1111/cei.13273. Epub 2019 Feb 27.

PMID:
30737776
8.

Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis.

Pérez-Baos S, Gratal P, Barrasa JI, Lamuedra A, Sánchez-Pernaute O, Herrero-Beaumont G, Largo R.

J Inflamm (Lond). 2019 Jan 29;16:2. doi: 10.1186/s12950-019-0206-2. eCollection 2019.

9.

Type 2 diabetes mellitus and osteoarthritis.

Veronese N, Cooper C, Reginster JY, Hochberg M, Branco J, Bruyère O, Chapurlat R, Al-Daghri N, Dennison E, Herrero-Beaumont G, Kaux JF, Maheu E, Rizzoli R, Roth R, Rovati LC, Uebelhart D, Vlaskovska M, Scheen A.

Semin Arthritis Rheum. 2019 Aug;49(1):9-19. doi: 10.1016/j.semarthrit.2019.01.005. Epub 2019 Jan 11. Review.

10.

Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice.

Conesa-Buendía FM, Llamas-Granda P, Larrañaga-Vera A, Wilder T, Largo R, Herrero-Beaumont G, Cronstein B, Mediero A.

J Bone Miner Res. 2019 May;34(5):923-938. doi: 10.1002/jbmr.3665. Epub 2019 Feb 25.

PMID:
30645771
11.

Patients' preferences for osteoarthritis treatment: the value of stated-preference studies.

Hiligsmann M, Pinto D, Dennison E, Al-Daghri N, Beaudart C, Branco J, Bruyère O, Conaghan PG, Cooper C, Herrero-Beaumont G, Jiwa F, Lems W, Rizzoli R, Thomas T, Veronese N, Reginster JY.

Aging Clin Exp Res. 2019 Jan;31(1):1-3. doi: 10.1007/s40520-018-1098-3. Epub 2019 Jan 4. No abstract available.

12.

2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJ, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L.

Ann Rheum Dis. 2019 Jan;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.

PMID:
30154087
13.

Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review.

Maheu E, Bannuru RR, Herrero-Beaumont G, Allali F, Bard H, Migliore A.

Semin Arthritis Rheum. 2019 Feb;48(4):563-572. doi: 10.1016/j.semarthrit.2018.06.002. Epub 2018 Jun 19. Review.

14.

Does anti-tumour necrosis factor alpha therapy exert a long-term structural benefit in hand osteoarthritis?

Roman-Blas JA, Keen H, Herrero-Beaumont G.

Rheumatology (Oxford). 2018 Nov 1;57(11):1879-1880. doi: 10.1093/rheumatology/key210. No abstract available.

PMID:
30053251
15.

Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation.

Pérez-Baos S, Prieto-Potin I, Román-Blas JA, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G.

Front Physiol. 2018 Apr 24;9:409. doi: 10.3389/fphys.2018.00409. eCollection 2018. Review.

16.

Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis.

Naredo E, Medina JP, Pérez-Baos S, Mediero A, Herrero-Beaumont G, Largo R.

Ultrasound Med Biol. 2018 Jul;44(7):1516-1524. doi: 10.1016/j.ultrasmedbio.2018.03.018. Epub 2018 Apr 24.

PMID:
29703511
17.

Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains.

Portal-Núñez S, Ardura JA, Lozano D, Martínez de Toda I, De la Fuente M, Herrero-Beaumont G, Largo R, Esbrit P.

Bone Joint Res. 2018 Jan;7(1):58-68. doi: 10.1302/2046-3758.71.BJR-2016-0242.R2.

18.

Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Reginster JL, Arden NK, Haugen IK, Rannou F, Cavalier E, Bruyère O, Branco J, Chapurlat R, Collaud Basset S, Al-Daghri NM, Dennison EM, Herrero-Beaumont G, Laslop A, Leeb BF, Maggi S, Mkinsi O, Povzun AS, Prieto-Alhambra D, Thomas T, Uebelhart D, Veronese N, Cooper C.

Semin Arthritis Rheum. 2018 Aug;48(1):1-8. doi: 10.1016/j.semarthrit.2017.12.003. Epub 2017 Dec 7. Review.

19.

Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis.

Larrañaga-Vera A, Lamuedra A, Pérez-Baos S, Prieto-Potin I, Peña L, Herrero-Beaumont G, Largo R.

Arthritis Res Ther. 2017 Dec 1;19(1):264. doi: 10.1186/s13075-017-1473-z.

20.

Osteoarthritis: Chondroitin sulfate - CONCEPT clear, uncertainties unchanged.

Herrero-Beaumont G, Largo R.

Nat Rev Rheumatol. 2017 Oct;13(10):576-577. doi: 10.1038/nrrheum.2017.131. Epub 2017 Aug 17. No abstract available.

PMID:
28814816
21.

Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis.

Little RD, Prieto-Potin I, Pérez-Baos S, Villalvilla A, Gratal P, Cicuttini F, Largo R, Herrero-Beaumont G.

Sci Rep. 2017 Jul 24;7(1):6311. doi: 10.1038/s41598-017-06581-6.

22.

Unexpected Bone Formation Produced by RANKL Blockade.

Portal-Núñez S, Mediero A, Esbrit P, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G.

Trends Endocrinol Metab. 2017 Oct;28(10):695-704. doi: 10.1016/j.tem.2017.06.003. Epub 2017 Jul 19. Review.

PMID:
28733136
23.

Reply.

Roman-Blas JA, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G.

Arthritis Rheumatol. 2017 Oct;69(10):2093-2094. doi: 10.1002/art.40212. Epub 2017 Aug 29. No abstract available.

24.

Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Pérez-Baos S, Barrasa JI, Gratal P, Larrañaga-Vera A, Prieto-Potin I, Herrero-Beaumont G, Largo R.

Br J Pharmacol. 2017 Sep;174(18):3018-3031. doi: 10.1111/bph.13932. Epub 2017 Aug 3.

25.

Erratum to: The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology.

Migliore A, Scirè CA, Carmona L, Herrero-Beaumont G, Bizzi E, Branco J, Carrara G, Chevalier X, Collaku L, Aslanidis S, Denisov L, Di Matteo L, Bianchi G, Diracoglu D, Frediani B, Maheu E, Martusevich N, Bagnato GF, Scarpellini M, Minisola G, Akkoc N, Ramonda R, Barskova T, Babic-Naglic D, Muelas JVM, Ionescu R, Rashkov R, Damjanov N, Cerinic MM.

Rheumatol Int. 2017 Aug;37(8):1237-1238. doi: 10.1007/s00296-017-3742-1. No abstract available.

PMID:
28523419
26.

The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology.

Migliore A, Scirè CA, Carmona L, Herrero-Beaumont G, Bizzi E, Branco J, Carrara G, Chevalier X, Collaku L, Aslanidis S, Denisov L, Di Matteo L, Bianchi G, Diracoglu D, Frediani B, Maheu E, Martusevich N, Bagnato GF, Scarpellini M, Minisola G, Akkoc N, Ramonda R, Barskova T, Babic-Naglic D, Muelas JVM, Ionescu R, Rashkov R, Damjanov N, Cerinic MM.

Rheumatol Int. 2017 Aug;37(8):1227-1236. doi: 10.1007/s00296-017-3700-y. Epub 2017 Apr 27. Erratum in: Rheumatol Int. 2017 Aug;37(8):1237-1238.

PMID:
28451793
27.

Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis.

Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, Kanis J, Laslop A, McAlindon T, Reiter S, Richette P, Rizzoli R, Reginster JY.

Drugs Aging. 2017 May;34(5):411. doi: 10.1007/s40266-017-0456-8. No abstract available.

PMID:
28349414
28.

Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.

Cooper C, Rannou F, Richette P, Bruyère O, Al-Daghri N, Altman RD, Brandi ML, Collaud Basset S, Herrero-Beaumont G, Migliore A, Pavelka K, Uebelhart D, Reginster JY.

Arthritis Care Res (Hoboken). 2017 Sep;69(9):1287-1296. doi: 10.1002/acr.23204. Epub 2017 Aug 8. Review. No abstract available.

29.

Clinical settings in knee osteoarthritis: Pathophysiology guides treatment.

Herrero-Beaumont G, Roman-Blas JA, Bruyère O, Cooper C, Kanis J, Maggi S, Rizzoli R, Reginster JY.

Maturitas. 2017 Feb;96:54-57. doi: 10.1016/j.maturitas.2016.11.013. Epub 2016 Nov 20. Review.

PMID:
28041596
30.

The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits.

Roman-Blas JA, Mediero A, Tardío L, Portal-Nuñez S, Gratal P, Herrero-Beaumont G, Largo R.

Eur J Pharmacol. 2017 Jan 5;794:8-14. doi: 10.1016/j.ejphar.2016.11.015. Epub 2016 Nov 12.

PMID:
27845067
31.

Corrigendum: The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction.

Villalvilla A, García-Martín A, Largo R, Gualillo O, Herrero-Beaumont G, Gómez R.

Sci Rep. 2016 Aug 19;6:30666. doi: 10.1038/srep30666. No abstract available.

32.
33.

The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction.

Villalvilla A, García-Martín A, Largo R, Gualillo O, Herrero-Beaumont G, Gómez R.

Sci Rep. 2016 Jul 7;6:29243. doi: 10.1038/srep29243. Erratum in: Sci Rep. 2016 Aug 19;6:30666.

34.

An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease.

Roman-Blas JA, Bizzi E, Largo R, Migliore A, Herrero-Beaumont G.

Expert Opin Pharmacother. 2016 Sep;17(13):1745-56. doi: 10.1080/14656566.2016.1201070. Epub 2016 Jul 4. Review.

PMID:
27326466
35.

Aromatase expression in human chondrocytes: An induction due to culture.

Villalvilla A, Gomez R, Lugo L, Lopez-Oliva F, Largo R, Herrero-Beaumont G.

Maturitas. 2016 Mar;85:27-33. doi: 10.1016/j.maturitas.2015.12.001. Epub 2015 Dec 7.

PMID:
26857876
36.

Meniscal degeneration in human knee osteoarthritis: in situ hybridization and immunohistochemistry study.

López-Franco M, López-Franco O, Murciano-Antón MA, Cañamero-Vaquero M, Fernández-Aceñero MJ, Herrero-Beaumont G, Gómez-Barrena E.

Arch Orthop Trauma Surg. 2016 Feb;136(2):175-83. doi: 10.1007/s00402-015-2378-4. Epub 2015 Dec 14.

PMID:
26667622
37.

Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis.

Prieto-Potin I, Largo R, Roman-Blas JA, Herrero-Beaumont G, Walsh DA.

BMC Musculoskelet Disord. 2015 Aug 27;16:226. doi: 10.1186/s12891-015-0664-5.

38.

DXA in the assessment of subchondral bone mineral density in knee osteoarthritis--A semi-standardized protocol after systematic review.

Sepriano A, Roman-Blas JA, Little RD, Pimentel-Santos F, Arribas JM, Largo R, Branco JC, Herrero-Beaumont G.

Semin Arthritis Rheum. 2015 Dec;45(3):275-83. doi: 10.1016/j.semarthrit.2015.06.012. Epub 2015 Jun 19.

PMID:
26188773
39.

Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.

Reginster JY, Reiter-Niesert S, Bruyère O, Berenbaum F, Brandi ML, Branco J, Devogelaer JP, Herrero-Beaumont G, Kanis J, Maggi S, Maheu E, Richette P, Rizzoli R, Cooper C.

Osteoarthritis Cartilage. 2015 Dec;23(12):2086-2093. doi: 10.1016/j.joca.2015.07.001. Epub 2015 Jul 14. Review.

40.

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty.

Arden N, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY.

Drugs Aging. 2015 Jul;32(7):525-35. doi: 10.1007/s40266-015-0276-7. Review.

41.

Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis.

Reginster JY, Cooper C, Hochberg M, Pelletier JP, Rizzoli R, Kanis J, Abadie E, Maheu E, Brandi ML, Devogelaer JP, Branco J, Herrero-Beaumont G, D'Hooghe P, Bruyère O.

Curr Med Res Opin. 2015 May;31(5):1041-5. doi: 10.1185/03007995.2015.1027183. Epub 2015 Mar 24.

PMID:
25753599
42.

Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis.

Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, Kanis J, Laslop A, McAlindon T, Reiter S, Richette P, Rizzoli R, Reginster JY.

Drugs Aging. 2015 Mar;32(3):179-87. doi: 10.1007/s40266-015-0243-3. Erratum in: Drugs Aging. 2017 May;34(5):411.

43.

Targeting subchondral bone in osteoporotic osteoarthritis.

Roman-Blas JA, Herrero-Beaumont G.

Arthritis Res Ther. 2014 Nov 25;16(6):494. doi: 10.1186/s13075-014-0494-0.

44.

Randomized clinical trials as reflexive-interpretative process in patients with rheumatoid arthritis: a qualitative study.

de Jorge M, Parra S, de la Torre-Aboki J, Herrero-Beaumont G.

Rheumatol Int. 2015 Aug;35(8):1423-30. doi: 10.1007/s00296-015-3218-0. Epub 2015 Jan 31.

PMID:
25636236
45.

TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.

Gómez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G.

Nat Rev Rheumatol. 2015 Mar;11(3):159-70. doi: 10.1038/nrrheum.2014.209. Epub 2014 Dec 16. Review.

PMID:
25512010
46.

Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study.

Ferreiro-Iglesias A, Calaza M, Perez-Pampin E, Lopez Longo FJ, Marenco JL, Blanco FJ, Narvaez J, Navarro F, Cañete JD, de la Serna AR, Gonzalez-Alvaro I, Herrero-Beaumont G, Pablos JL, Balsa A, Fernandez-Gutierrez B, Caliz R, Gomez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2014 Sep 27;16(5):436. doi: 10.1186/s13075-014-0436-x.

47.

SDF-1 signaling: a promising target in rheumatic diseases.

Villalvilla A, Gomez R, Roman-Blas JA, Largo R, Herrero-Beaumont G.

Expert Opin Ther Targets. 2014 Sep;18(9):1077-87. doi: 10.1517/14728222.2014.930440. Epub 2014 Jun 20. Review.

PMID:
24950016
48.

Tocilizumab in refractory aortitis: study on 16 patients and literature review.

Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, Mata C, Melchor S, Aurrecoechea E, Calvo-Alén J, Lluch P, Moll C, Mínguez M, Herrero-Beaumont G, Bravo B, Rubio E, Freire M, Peiró E, González-Vela C, Rueda-Gotor J, Pina T, Palmou-Fontana N, Calvo-Río V, Ortiz-Sanjuán F, González-Gay MÁ.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S79-89. Epub 2014 May 15.

PMID:
24854377
49.

Selective estrogen receptor modulators (SERMs): new alternatives for osteoarthritis?

Lugo L, Villalvilla A, Largo R, Herrero-Beaumont G, Roman-Blas JA.

Maturitas. 2014 Apr;77(4):380-4. doi: 10.1016/j.maturitas.2014.01.016. Epub 2014 Feb 15. Review.

PMID:
24602552
50.

Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.

Alejandre N, Ruiz-Palacios A, García-Aparicio AM, Blanco-Kelly F, Bermúdez S, Fernández-Sanz G, Romero FI, Aróstegui JI, Ayuso C, Jiménez-Alfaro I, Herrero-Beaumont G, Sánchez-Pernaute O.

Rheumatology (Oxford). 2014 Jun;53(6):1095-9.

PMID:
24501247

Supplemental Content

Loading ...
Support Center